Amplity Health, a global medical and commercial partner to biopharmaceuticals and portfolio company of Altamont Capital Partners, is merging with The Lynx Group, a communications firm focused on oncology and complex drugs.
The partnership will create a differentiated firm offering comprehensive medical and commercial services to clients and patients. Amplity’s capabilities include clinical and medical outsource teams, clinical and medical capability development, diagnostic and precision medicine services, communications, and more. The Lynx Group provides medical communications focused on oncology and rare disease states. The firm is partnered with over 50 pharma and biotech companies around the globe.
“Medical and commercial strategies for our biopharmaceutical clients have become highly specialized, and the new entry point for commercial conversations is when clinical, medical, and specialist professionals are framing the scientific narrative and the payer/patient value proposition,” added Michael Griffith, Amplity CEO and president. “Lynx engages with a unique combination of oncology and complex drug experts to create proprietary medical communications, produce topical and relevant events with their association partners, and develop high-quality scientific messages and publications that shape drug development and launch.”
SVB Leerink acted as financial advisor and Ropes & Gray served as legal counsel to Amplity Health in the transaction. Cain Brothers served as exclusive financial advisor and Greenberg Traurig served as legal counsel to The Lynx Group.